Literature DB >> 10037735

Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional.

A D Gibson1, J A Lamerdin, P Zhuang, K Baburaj, E H Serpersu, C B Peterson.   

Abstract

A primary heparin-binding site in vitronectin has been localized to a cluster of cationic residues near the C terminus of the protein. More recently, secondary binding sites have been proposed. In order to investigate whether the binding site originally identified on vitronectin functions as an exclusive and independent heparin-binding domain, solution binding methods have been used in combination with NMR and recombinant approaches to evaluate ligand binding to the primary site. Evaluation of the ionic strength dependence of heparin binding to vitronectin according to classical linkage theory indicates that a single ionic bond is prominent. It had been previously shown that chemical modification of vitronectin using an arginine-reactive probe results in a significant reduction in heparin binding (Gibson, A., Baburaj, K., Day, D. E., Verhamme, I. , Shore, J. D., and Peterson, C. B. (1997) J. Biol. Chem. 272, 5112-5121). The label has now been localized to arginine residues within the cyanogen bromide fragment-(341-380) that contains the primary heparin-binding site on vitronectin. One- and two-dimensional NMR on model peptides based on this primary heparin-binding site indicate that an arginine residue participates in the ionic interaction and that other nonionic interactions may be involved in forming a complex with heparin. A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for the site in the structure of the native protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037735     DOI: 10.1074/jbc.274.10.6432

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways.

Authors:  Hong-Beom Bae; Jaroslaw W Zmijewski; Jessy S Deshane; Degui Zhi; Lawrence C Thompson; Cynthia B Peterson; David D Chaplin; Edward Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

2.  A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma.

Authors:  Yang Ling; Jia Chen; Min Tao; Xiaoyuan Chu; Xizhi Zhang
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

3.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

4.  Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells.

Authors:  Claudia Sa E Cunha; Natalie J Griffiths; Mumtaz Virji
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

5.  Sialylation of vitronectin regulates stress fiber formation and cell spreading of dermal fibroblasts via a heparin-binding site.

Authors:  Yasunori Miyamoto; Mio Tanabe; Kimie Date; Kanoko Sakuda; Kotone Sano; Haruko Ogawa
Journal:  Glycoconj J       Date:  2016-03-15       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.